Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other equities analysts also recently weighed in on the stock. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Stifel Nicolaus restated a “buy” rating and set a $23.00 target price (down from $24.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, July 31st. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, July 30th. Finally, Wedbush restated a “buy” rating and set a $42.00 target price on shares of Lexicon Pharmaceuticals in a report on Monday, June 18th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $24.60.

Shares of LXRX stock opened at $10.39 on Friday. The company has a debt-to-equity ratio of -45.80, a quick ratio of 2.68 and a current ratio of 2.71. The firm has a market capitalization of $1.16 billion, a PE ratio of -8.18 and a beta of 0.33. Lexicon Pharmaceuticals has a 12 month low of $7.67 and a 12 month high of $15.16.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, July 30th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.02. The business had revenue of $13.75 million for the quarter, compared to analyst estimates of $15.88 million. Lexicon Pharmaceuticals had a negative net margin of 137.32% and a negative return on equity of 369.13%. The firm’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. analysts anticipate that Lexicon Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.

In other Lexicon Pharmaceuticals news, VP James F. Tessmer sold 10,000 shares of the company’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $12.91, for a total value of $129,100.00. Following the transaction, the vice president now directly owns 35,643 shares in the company, valued at $460,151.13. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Public Equities L.P. Invus acquired 138,700 shares of the firm’s stock in a transaction on Friday, May 25th. The stock was bought at an average price of $9.62 per share, for a total transaction of $1,334,294.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,924,615 shares of company stock worth $22,552,542. 6.10% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at $205,000. Tocqueville Asset Management L.P. acquired a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at $164,000. BlackRock Inc. increased its holdings in shares of Lexicon Pharmaceuticals by 4.6% in the second quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock valued at $53,066,000 after purchasing an additional 195,461 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Lexicon Pharmaceuticals by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock valued at $2,893,000 after purchasing an additional 14,426 shares during the last quarter. Finally, Price Capital Management Inc. acquired a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at $1,352,000.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.